# EDGAR Filing Document

**Accession Number:** 0001138723
**File Stem:** 0001437749-26-011313
**Filing Date:** 2026-4
**Character Count:** 11243
**Document Hash:** 145c44b9ab458e08ad3d71b80ec4b349
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-011313.hdr.sgml**: 20260406

**ACCESSION NUMBER**: 0001437749-26-011313

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260406

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260406

**DATE AS OF CHANGE**: 20260406

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ACCURAY INC
- **CENTRAL INDEX KEY:** 0001138723
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208370041
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33301
- **FILM NUMBER:** 26839709

**BUSINESS ADDRESS:**
- **STREET 1:** 1240 DEMING WAY
- **CITY:** MADISON
- **STATE:** WI
- **ZIP:** 53717
- **BUSINESS PHONE:** 608-824-2800

**MAIL ADDRESS:**
- **STREET 1:** 1240 DEMING WAY
- **CITY:** MADISON
- **STATE:** WI
- **ZIP:** 53717

?xml version='1.0' encoding='ASCII'? aray20260402_8k.htm

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **WASHINGTON, D.C. 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 6, 2026**<br>

------

## ACCURAY INCORPORATED
**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-33301** | **20-8370041** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br> **Identification No.)** |
| **1240 Deming Way** |  |  |
| **Madison, Wisconsin** |  | **53717-1954** |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant**'**s Telephone Number, Including Area Code: 608 824-2800**<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | ARAY | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01. Regulation FD Disclosure.**

On April 6, 2026, Accuray Incorporated (the "Company") issued a press release regarding the appointment of Paul Miele as the Company's SVP, Chief Commercial Officer, effective April 6, 2026. A copy of this press release is included as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 7.01 disclosure, including Exhibit 99.1, is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |

---

---

| | |
|:---|:---|
| 99.1 | [Press Release dated April 6, 2026.](ex_941350.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **ACCURAY INCORPORATED** |
| Date: | April 6, 2026 | By: | /s/ Ali Pervaiz |
|  |  |  | Ali Pervaiz<br> *Senior Vice President & Chief Financial Officer* |

---

## Exhibit 99.1

EXHIBIT 99.1

Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

**MADISON, Wis., April 6, 2026** — Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of **Paul Miele** as **Senior Vice President and Chief Commercial Officer**, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio.

"Paul brings deep global commercial leadership experience and a strong track record of driving transformation and sales growth in complex medical technology businesses," said **Steve La Neve, President and Chief Executive Officer of Accuray**. "His background in rebuilding commercial operating models, accelerating capital equipment and services sales, and unlocking recurring revenue opportunities will be instrumental as we continue to strengthen our commercial performance and position Accuray for long-term value creation."

Mr. Miele is a seasoned commercial executive with nearly two decades of experience leading and scaling global capital medical device businesses across the Americas, EMEA, and APAC. Most recently, Mr. Miele served as **Business Unit Leader and General Manager for the MONARCH**™ **robotic platform at Johnson & Johnson MedTech**, where he was recruited to lead a commercial turnaround. In that role, he rebuilt the commercial operating model, reactivated the installed base, strengthened service and solutions monetization, and accelerated capital equipment sales, reversing a revenue decline trend and generating double digit percentage annual sales growth during his tenure. Prior to Monarch, Mr. Miele was similarly successful in senior commercial roles at Globus Medical and Intuitive Surgical.

As Chief Commercial Officer, Mr. Miele will be responsible for defining and executing Accuray's global commercialization strategy across sales, marketing, pricing and market access, commercial partnerships, and launch excellence.

"Accuray has a strong foundation of innovation, a large installed base, a group of dedicated distribution partners, and a meaningful opportunity to further strengthen its commercial impact worldwide," said **Paul Miele**. "Most importantly, Accuray's products are vital to treating cancer patients in 70+ countries around the world. I'm excited to join the team and help drive growth in systems and services sales, with a particular focus on marketing and selling value-added solutions to our customers, on commercial execution, and on carrying out Accuray's mission for the benefit of countless customers and patients."

<u>About</u><u> </u><u>Accuray</u>

Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.

<u>Safe Harbor Statement</u>

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, expectations regarding the Company's new Chief Commercial Officer and ability to strengthen commercial performance. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 17, 2026, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

<u>Media Contact</u><br> Steve Monroe <br> Accuray <br> smonroe@accuray.com

<u>Investor Contact</u><br> Aman Patel, CFA<br> Investor Relations, ICR-Westwicke<br> aman.patel@westwicke.com